France-based Onxeo SA, which has a US approved drug for peripheral T-cell lymphoma and a late stage drug for primary liver cancer, has decided to reinforce its scientific expertise with the appointment of a new chief scientific officer and a new chief medical officer. The new CSO, Françoise Bono, previously was the chief oncologist at Evotec AG and before that, had a long career with Sanofi SA. She will take charge of Onxeo’s preclinical research. The new CMO, Olivier de Beaumont, will lead clinical development and regulatory affairs. Dr de Beaumont, who holds a medical degree as well as a master of business administration, previously worked for the allergy specialist Stallergenes Greer Plc as head of global clinical development, pharmacovigilance and medical affairs.
Onxeo announced the appointment on 1 March 2017.
Copyright 2017 Evernow Publishing Ltd